TR

Tridek-One’s website

Paris, FR · 5 known investors

tridekone.com ↗

Tridek-One Therapeutics develops bispecific antibodies that agonize the CD31 ITIM inhibitory checkpoint receptor to modulate immune cell activation for inflammatory and autoimmune diseases. Its lead program is a CD31×GPVI bispecific antibody for thromboinflammatory cardiovascular diseases, aiming to provide antithrombotic and anti-inflammatory effects while minimizing bleeding risk.

Investors · 5

AD

Advent Life Sciences✓ verifiedLondon

BI

Bioqube Ventures✓ verifiedBrussels · $108K – $6.5M

BP

Bpifrance✓ verifiedParis, Ile-De-France · $270K

PU

Pureos Bioventures✓ verifiedPfäffikon

AD

AdBio partnersParis